RxDoctor Payments Data

Emily Ross, MD

Family Medicine · Bowling Green, KYNPI 1255960431

Payments from drug & device makers

$2,170in general payments, 2019–2025

Across 125 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$795
  • Pfizer$251
  • AstraZeneca$197
  • Johnson & Johnson$156
  • Astellas Pharma US Inc$148
  • Novo Nordisk$97
  • plus $526 from 14 others

What the payments were for

  • Food & beverage$2,170100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,170 in reported general payments places this provider in the 70th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$15,240
Medicare patients
44
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$43,650
MounjaroTirzepatide30$33,888
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$24,458
FarxigaDapagliflozin Propanediol14$16,976
EliquisApixaban12$12,916
Tramadol Hcl11$1,061
Albuterol Sulfate HfaAlbuterol Sulfate32$681
Omeprazole48$578
Levothyroxine Sodium39$515
Atorvastatin Calcium102$508
Gabapentin49$427
Rosuvastatin Calcium28$356
Metoprolol Succinate29$336
Potassium Chloride18$274
Fluticasone Propionate41$254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$97$43,65038 claims
Lilly USA, LLCMounjaro$82$33,88830 claims
GSKTrelegy Ellipta$30$24,45832 claims
AstraZenecaFarxiga$197$16,97614 claims
PfizerEliquis$251$12,91612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →